EU approves first vaccine against common respiratory virus
The European Commission has approved the world’s first vaccine for Respiratory Syncytial Virus (RSV) in adults aged 60 and over.
GSK, the maker of the vaccine called Arexvy, stated that this authorization allows eligible adults to be vaccinated against RSV for the first time.
RSV can cause severe illness in vulnerable populations and has led to approximately 20,000 in-hospital deaths each year in Europe among adults aged 60 and over.
The market for RSV vaccines is projected to exceed $10 billion in the coming decade.
